Antipodes Partners
MRK icon

Antipodes Partners’s Merck MRK Stock Holding History

Antipodes Partners’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$131M Sell
904,674
-192,835
-18% -$26.6M 2.42% 13
2026
Q2 		$141M Sell
1,097,509
-343,757
-24% -$40.2M 2.58% 11
2026
Q1 		$173M Sell
1,441,266
-134,545
-9% -$15.5M 3.34% 5
2025
Q4 		$166M Sell
1,575,811
-95,741
-6% -$8.99M 3.48% 6
2025
Q3 		$140M Sell
1,671,552
-142,708
-8% -$11.8M 3.15% 12
2025
Q2 		$144M Sell
1,814,260
-153,710
-8% -$12.2M 4.45% 7
2025
Q1 		$177M Buy
1,967,970
+119,339
+6% +$11.1M 5.53% 5
2024
Q4 		$184M Buy
1,848,631
+272,815
+17% +$28.1M 6.39% 4
2024
Q3 		$179M Sell
1,575,816
-99,830
-6% -$11.9M 6.2% 3
2024
Q2 		$207M Sell
1,675,646
-213,659
-11% -$27.5M 7.54% 1
2024
Q1 		$249M Sell
1,889,305
-285,599
-13% -$35.2M 7.88% 1
2023
Q4 		$237M Sell
2,174,904
-95,095
-4% -$9.9M 7.41% 1
2023
Q3 		$237M Buy
2,269,999
+520,841
+30% +$56.1M 7.61% 1
2023
Q2 		$202M Sell
1,749,158
-107,402
-6% -$12.2M 6.97% 1
2023
Q1 		$198M Buy
1,856,560
+1,121
+0.1% +$121K 6.85% 1
2022
Q4 		$206M Sell
1,855,439
-409,457
-18% -$41.9M 7.38% 1
2022
Q3 		$195M Buy
2,264,896
+316,431
+16% +$28.2M 7.83% 1
2022
Q2 		$178M Sell
1,948,465
-239,177
-11% -$21.2M 7.4% 1
2022
Q1 		$179M Buy
2,187,642
+222,174
+11% +$17.5M 6.36% 2
2021
Q4 		$151M Buy
1,965,468
+62,956
+3% +$5.01M 5.41% 7
2021
Q3 		$143M Sell
1,902,512
-154,947
-8% -$11.8M 4.88% 6
2021
Q2 		$160M Sell
2,057,459
-72,933
-3% -$5.42M 5.77% 3
2021
Q1 		$157M Buy
2,130,392
+108,406
+5% +$8M 6.35% 3
2020
Q4 		$158M Buy
2,021,986
+202,783
+11% +$15.5M 6.86% 3
2020
Q3 		$144M Sell
1,819,203
-161,405
-8% -$12.6M 6.6% 4
2020
Q2 		$146M Buy
1,980,608
+39,093
+2% +$2.94M 6.62% 3
2020
Q1 		$143M Buy
+1,941,515
New +$153M 7.46% 3
2019
Q4 		– Sell
-1,853,247
Closed -$149M – 33
2019
Q3 		$149M Buy
1,853,247
+317,954
+21% +$25.5M 7.1% 3
2019
Q2 		$123M Buy
+1,535,293
New +$118M 5.64% 8

Other funds holding MRK

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Antipodes Partners's MRK Position: Q3 2026 in Review

Antipodes Partners reduced its Merck (MRK) stake by 18% in Q3 2026, selling an estimated $26.6M and leaving 904,674 shares worth $131M. The position accounts for 2.42% of the portfolio, ranked #13.

Antipodes Partners first reported a position in MRK in Q2 2019 and has held it in 29 quarters since. The position peaked at $249M in Q1 2024. 2,434 funds tracked by Wall St. Rank hold MRK as of Q3 2026.

  • Antipodes Partners held 904,674 shares of Merck worth $131M as of Q3 2026.
  • Antipodes Partners sold 192,835 Merck shares in Q3 2026, an estimated $26.6M.
  • Merck made up 2.42% of Antipodes Partners's portfolio in Q3 2026, its #13 holding.
  • Antipodes Partners first reported a position in Merck in Q2 2019 and has held it in 29 quarters since.
  • Antipodes Partners's Merck position peaked at $249M in Q1 2024.
  • 2,434 funds tracked by Wall St. Rank held Merck as of Q3 2026.

Based on Antipodes Partners's 13F filing for Q3 2026, filed 5 Nov 2026.